Anti-Fibril Depleters: The Dawn of a New Treatment Era in Transthyretin Amyloid Cardiomyopathy?

Michel G. Khouri; Jan M. Griffin

doi:10.1161/circulationaha.125.078276

Anti-Fibril Depleters: The Dawn of a New Treatment Era in Transthyretin Amyloid Cardiomyopathy?

M Michel G. Khouri (Department of Medicine, Duke University Hospital System, Durham, NC (M.G.K.).) J Jan M. Griffin (Department of Medicine, Medical University of South Carolina, Charleston, SC (J.M.G.).)

View Original

APA MLA Chicago BibTeX RIS

Article Details

Journal Circulation

Volume / Issue Vol. 153, Issue 4

Published January 27, 2026

Pages 226-229

DOI 10.1161/circulationaha.125.078276

ISSN 0009-7322

Publisher Lippincott Williams & Wilkins

Journal Info

Circulation

Lippincott Williams & Wilkins

ISSN: 0009-7322 Health Sciences

Authors (2)

M

Michel G. Khouri

Department of Medicine, Duke University Hospital System, Durham, NC (M.G.K.).

J

Jan M. Griffin

Department of Medicine, Medical University of South Carolina, Charleston, SC (J.M.G.).

Anti-Fibril Depleters: The Dawn of a New Treatment Era in Transthyretin Amyloid Cardiomyopathy?

Article Details

Journal Info

Authors (2)

Related Articles from this Journal

Occupational Radiation Safety in Electrophysiology During Pregnancy: Evaluating Uterine Radiation Doses During Catheter Ablations and Device Implantations

Response by Rogers et al to Letter Regarding, “Deep Learning-Based Continuous QT Monitoring to Identify High-Risk Prolongation Events After Class III Antiarrhythmic Initiation”

Clinical Cardiology at the Crossroads: Perspectives on the Next Era at <i>Circulation</i>

ABHD11-Mediated mtDNA Transcription Restored Mitochondrial Function to Attenuate Cardiomyocyte Ferroptosis After Myocardial Infarction

Letter by Li et al Regarding Article, “Deep Learning-Based Continuous QT Monitoring to Identify High-Risk Prolongation Events After Class III Antiarrhythmic Initiation”